home / stock / huma / huma news

HUMA News and Press, Humacyte Inc. From 11/02/23

Stock Information
Company Name: Humacyte Inc.
Stock Symbol: HUMA
Market: NASDAQ
Website: humacyte.com
Menu
HUMA HUMA Quote HUMA Short HUMA News HUMA Articles HUMA Message Board
Get HUMA Alerts

News, Short Squeeze, Breakout and More Instantly...
HUMA - Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the third quarter ended September 30, 2023, on ...
HUMA - Humacyte Publishes Preclinical Results Showing Human Acellular Vessel(TM) (HAV(TM)) Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model

DURHAM, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced publication of a preclinical study showing the potential for its investigati...

HUMA - Humacyte to Present at the Cantor Global Healthcare Conference

DURHAM, N.C., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief ...

HUMA - Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023

DURHAM, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced it will host an in-person KOL event on Wednesday, September 20, 2023 at 3:0...
HUMA - CARA, LOVE and RUM are among after hour movers

2023-09-15 16:49:26 ET Gainers: Omeros Corporation ( NASDAQ: OMER ) +5% . The Lovesac Company ( LOVE ) +4% . Patriot Transportation  ( PATI ) +3% . Cipher Mining ( CIFR ) +2% . Humacyte ( HUMA ) +2% . Losers: San...

HUMA - Avalo, MoonLake, Acelyrin among healthcare movers

2023-09-12 10:11:31 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

HUMA - Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel(TM) (HAV(TM)) in Treatment of Patients with Vascular Trauma

-- Single-arm clinical trial was a success and showed the HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks -- -- BLA planned to be filed with FDA in 4 th Quarter 2023 -- ...
HUMA - Biggest stock movers today: WestRock, Oracle and more

2023-09-12 06:14:55 ET Related stories Compare metrics for HUMA to ORCL, SGHT, SLRN, WRK WestRock: Solid Asset-Based, But (Likely) Not The Right Time Reevaluating Acelyrin: The Impact Of Mixed Izokibep Results (Rating Downgrade) Oracle Corporation ( ORCL ...

HUMA - Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel(TM) (HAV(TM)) Tuesday, September 12, 2023 at 8:00 AM ET

DURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will host a virtual webinar to announce top line data results from its Phase 2/3 V005 ...

HUMA - Results From Mayo Clinic Clinical Study of Humacyte's Human Acellular Vessel(TM) (HAV(TM)) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference

DURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of results from a Food and Drug Administration (FDA)-regul...
Previous 10 Next 10